Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research

5265 - First analysis of patients (p) with stage IV Non-Small Cell Lung Cancer (NSCLC) of the Thoracic Tumor Registry (RTT) of the Spanish Lung Cancer Group (SLCG)


20 Oct 2018


Poster display session: Biomarkers, Gynaecological cancers, Haematological malignancies, Immunotherapy of cancer, New diagnostic tools, NSCLC - early stage, locally advanced & metastatic, SCLC, Thoracic malignancies, Translational research



Tumour Site


Enric Carcereny Costa


Annals of Oncology (2018) 29 (suppl_8): viii493-viii547. 10.1093/annonc/mdy292


E. Carcereny Costa1, D. Rodriguez-Abreu2, M. Guirado3, R. López-Castro4, B. Massutí5, J. Bosch Barrera6, E. Nogueron Martnez7, M..A. Sala Gonzalez8, M. Domine Gomez9, E. Del Barco Morillo10, S. Cerezo Gonzalez11, M. Dorta Suarez12, J. Casal Rubio13, C. Camps14, M.A. Muñoz15, R. de las Peñas16, J.A. Ortega dominguez17, J.L. Gonzalez-Larriba18, R. Bernabe Caro19, M. Provencio Pulla20

Author affiliations

  • 1 Medical Oncology, Catalan Institute of Oncology (ICO Badalona), Hospital Germans Trias i Pujol, 8916 - Badalona/ES
  • 2 Servicio Oncología Médica, Hospital Insular De Gran Canaria, Las Palmas/ES
  • 3 Medical Oncolgy, Hospital General Universitario de Elche, 3203 - Elche/ES
  • 4 Medical Oncology, Hospital Universitario Clínico de Valladolid, Valladolid/ES
  • 5 Oncología Médica, Hospital General Universitario Alicante, Alicante/ES
  • 6 Medical Oncology, Catalan Institute of Oncology (ICO)-Hospital Universitari Josep Trueta, 17007 - Girona/ES
  • 7 Oncologia, Complejo Hospitalario Universitario de Albacete, 2006 - Albacete/ES
  • 8 Medical Oncology, HOSPITAL DE BASURTO, 0000000 - Vizcaya/ES
  • 9 Medical Oncology, University Hospital "Fundacion Jimenez Diaz", 28040 - Madrid/ES
  • 11 Medical Oncology, Hospital General Mancha Centro, 13600 - Alcazar de San Juan/ES
  • 12 Medical Oncology, Hospital Universitario Nuestra Señora de Candelaria, 38010 - Santa Cruz de Tenerife/ES
  • 13 Medical Oncology, Hospital Meixoeiro, 36214 - Vigo/ES
  • 14 Medical Oncology, Consorcio Hospital General Universitario de Valencia, 46014 - Valencia/ES
  • 16 Medical Oncology, Consorcio Hospitalario Provincial de Castellon, 00000 - CASTELLON/ES
  • 17 Oncolgy, Hospital QuironSalud, 0000 - Malaga/ES
  • 18 Medical Oncology, Hospital Clinico Universitario San Carlos, 28040 - Madrid/ES
  • 19 Medical Oncology, Hospital Universitario Virgen del Rocio, 41013 - Sevilla/ES
  • 20 Servicio De Oncología Médica, Hospital Universitario Puerta de Hierro - Majadahonda, 28222 - Majadahonda/ES


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5265


In September 2016, the SLCG began a RTT in 53 Spanish hospitals. In this study, we present data on patients with NSCLC with advanced disease.


The study comprises all the patients included in the RTT since September 2016 with stage IV disease. Progressionfree survival (PFS) and overall survival (OS) were evaluated with the Kaplan-Meier curves and the groups were compared using the Log-rank test. The variables related with the patients that were analyzed included: age, gender, smoking habit, comorbidities, performance status (PS) by ECOG and histology of the tumor. The molecular tests performed in the group of patients with advanced disease were also analyzed. We also analyzed the treatment received in this patient cohort.


Out of the total of 2361 patients included, diagnosed between July 1991 and April 2018, 1194 had stage IV NSCLC. Mean age was 63.2 years, 824 (69%) were males, 473 (39.6%) active smokers and 475 (39.8%) ex-smokers. The most frequent histology was adenocarcinoma, in 894 patients (74.9%), and squamous cell, in 220 patients (18.4%). A total of 78.6% (938) of the patients had some type of comorbidity: HBP (38.5%), dyslipidemia (28.1%), diabetes mellitus (16.3%) and COPD (14.7%). A total of 978 patients (81.9%) underwent some type of molecular test. The EGFR analysis was performed in 900 patients (75.4%), and was positive in 25.6%. ALP was analyzed in 763 patients (63.9%), mostly by IHC (44.7%), 5.2% being positive by this method. Of the total, 158 patients (13.2%) did not receive any treatment, 530 patients (44.4%) received 1 treatment line, 295 patients (24.7%) two lines, 128 patients (10.7%) three lines, and 30 patients (2.5%) 4 or more lines. A total of 60.9% of the patients received a platinum doublet in first line, the most commonly used being the combination of platinum with pemetrexed (34%). 1171 patients are evaluable for overall survival, with a median survival of 17.4 m (95% CI 14.6-20.2 m).


In this cohort of patients, the clinical characteristics are those expected for this group of patients with advanced disease. However, a greater percentage than that expected of the EGFR mutations appears, perhaps due to a population supraselection.

Clinical trial identification

Legal entity responsible for the study

Spanish Lung Cancer Group / Grupo Español de Cáncer de Pulmón (SLCG/GECP).


Lilly, Msd, Novartis.

Editorial Acknowledgement


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.